| 1. |
1 Hemkens LG, Grouven U, Bender R,
et al . Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia , 2009, 52(9): 1732-1744.
|
| 2. |
Jonasson JM, Ljung R, Talback M, et al . Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia , 2009, 52(9): 1745-1754.
|
| 3. |
Kuriki K, Hirose K, Tajima K, et al . Diabetes and cancer risk for all and specific sites among Japanese men and women. Cancer Pre , 2007, 16(1): 83-89.
|
| 4. |
Huxley R, Ansary-Moghaddam A, Berrington de gonzalez A, et al . Type-Ⅱdiabetes and pancreatic cancer: a meta-analysis of 36 studies. Brit J of Cancer , 2005, 92(11): 2076-2083.
|
| 5. |
Larsson SC, Orsini N, Wolk A. Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis. Nati Cancer Inst , 2005, 97(22): 1679-1687.
|
| 6. |
Hemminki K, Li XJ, Sundquist J, et al . Risk of Cancer Following Hospitalization for Type 2 Diabetes. Oncologist , 2010, 15(6): 548-555.
|
| 7. |
Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia ,.
|
| 8. |
Currie CJ, Poole CD, Gale EA. The influnece of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia , 2009, 52(9): 1766-1777.
|
| 9. |
Rosenstock J, Fonseca V, McGill JB, et al . Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomized, open-label study. Diabetologia , 2009, 52(9): 1971-1973.
|
| 10. |
Dejgaard A, Lynggaard H, Rastam J, et al . No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia , 2009, 52(12): 2507-2512.
|
| 11. |
Home PD, Lagarenne P. Combined randomised control trial experience of malignancies in studies using insulin glargine. Diabetologia , 2009, 52(12): 2499-2506.
|
| 12. |
ORIGIN Trial Investigators, Gerstein H, Yusuf S, et al . Rationale design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J , 2008, 155(1): 26-32.
|
| 13. |
Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia , 2011, 54(1): 25-31.
|
| 14. |
, 52(9): 1755-1765.
|
